Transactions - Asian Capital

Mergers and Acquisitions

Restructuring and Resumption of Trading

Financial Advisory

Fund Raising and IPO

Type

Industry

United Gene High-Tech Group Limited (formerly known as Far East Pharmaceutical Technology Company Limited)

Stock Code: 399
Announcement Date: 22 November, 2010
Deal Size (HK$): 78 Million
Status: Closed

Major and connected transactions in relation to the acquisition of entire equity interests of (1) Fudan Health (Guang Dong) Ltd. and (2) Fudan Health International (HK) Limited and continuing connected transactions

Freeman Corporation Limited

Stock Code: 279
Announcement Date: 01 November, 2010
Deal Size (HK$): 200 Million
Status: Closed

(1) Very substantial disposal in relation to the deemed Disposal arising from Subscription for New Shares by an investor in a non-wholly owned subsidiary; and (2) major transaction in relation to the provision of financial assistance under the Loan Facility

Tack Fiori International Group Limited (formerly known as Tack Fat Group International Limited)

Stock Code: 928
Announcement Date: 31 August, 2010
Deal Size (HK$): 1,349.1 Million
Status: Closed

Restructuring of Tack Fat Group International Limited (Provisional Liquidators Appointed) involving, inter alia, (1) proposed Open Offer on the basis of 339 Offer Shares for every 5 New Shares held on the Record Date; (2) proposed issue of Convertible Bonds; (3) application for Whitewash Waiver; and (4) Special Deal

Skyfame Realty (Holdings) Limited

Stock Code: 59
Announcement Date: 19 August, 2010
Deal Size (HK$): 1,253 Million
Status: Closed

Very Substantial Disposal in relation to Refreshment of the 10% general limited under the Share Option Scheme

Pan Asia Mining Limited

Stock Code: 8173
Announcement Date: 20 July, 2010
Deal Size (HK$): 3,000 Million
Status: Closed

(1) Issue of the Subscription Shares and the 2010 Convertible Bonds; (2) Debt Restructuring Agreement involving connected transaction; (3) application for the Whitewash Waiver and consent to the Special Deal; (4) grant of Special Mandate; and (5) increase in authorised share capital